Leukemia in 2020 and Beyond
CML — First-Line TKI Landscape and Relapsed/Refractory and New Targets. ALL — Role of Monoclonal Antibodies and Bispecific Engagers, and the Role of CAR T Cells.
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, US
Faculty Members
Aaron Logan, MD, PhD
UCSF Health, San Francisco, CA, USA
Amir Fathi, MD
Massachusetts General Hospital, Boston, MA, USA
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Javier Pinilla, MD, PhD
Moffitt Cancer Center, Tampa, FL, USA
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York City, NY, USA
Jerald Radich, MD
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Naval Daver, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL, USA
Richard Stone, MD
Dana-Farber Cancer Institute, Boston, MA, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- CML: First-Line TKI Landscape
- CML: Relapsed/Refractory and New Targets
- ALL: Genetic Subsets
- ALL: Role of Monoclonal Antibodies and Bispecific Engagers
- ALL: Role of CAR T Cells
- MDS: Low-Risk Disease
- MDS: High-Risk Disease
- AML: Patient Subsets
- AML: Targeting FLT3 and BCL-2
- AML: New Therapeutic Targets
